Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation : a prospective randomized trial
Joint Authors
Najib, Ayman Mahir
Mashali, Muhammad al-Sayyid
Abu al-Majd, Muhammad Mujahid
Denewar, Ahmad Abd al-Fattah
Abd al-Rahman, Ahmad Mansur
al-Saftawi, Muhammad Muhammad
Dunya, Ahmad Faruq
Abbas, Muhammad Hamid
Bakr, Muhammad Adil
Ghunaym, Muhammad Ahmad
Source
Saudi Journal of Kidney Diseases and Transplantation
Issue
Vol. 29, Issue 6 (31 Dec. 2018), pp.1267-1273, 7 p.
Publisher
Saudi Center for Organ Transplantation
Publication Date
2018-12-31
Country of Publication
Saudi Arabia
No. of Pages
7
Main Subjects
Abstract EN
Immunosuppression management in clinical transplantation aims to balance delivery of efficacy against adverse reactions using therapeutic drug monitoring.
Adherence to posttransplant immunosuppressive medications and minimizing variability in drug exposure are important considerations in preventing rejection and maximizing overall transplant outcomes.
The availability of once-daily tacrolimus may add a potential benefit by simplifying immunosuppressive regimens, though improving compliance among transplant recipients.
The aim of our study is to investigate the safety and efficacy of the once-daily formulation of tacrolimus (Advagraf) against the usually used twice daily tablets (Prograf).
A prospective randomized trial 1:2 was designed for 99 consecutive live-related renal transplant recipients who received their grafts at a single center (study group, Advagraf, 33 recipients and control group, Prograf, 66 recipients).
The demographic data were homogeneous among both groups regarding donors and patients' characteristics.
Posttransplant hypertension, infection, malignancy, and diabetes mellitus were comparable among both groups.
Renal function and rejection episodes showed no statistical significance among recipients of both groups.
Despite slight higher Advagraf unit doses, there was no statistical difference regarding the tacrolimus trough levels, between the two groups.
Our singlecenter experience revealed that the availability of once-daily tacrolimus formulation could give potential benefit of improved medication compliance and better allograft outcomes by decreasing pill burden and thereby simplifying dosing schedule, Advagraf was non-inferior to twice-daily tacrolimus regarding safety and efficacy.
Although being nonsignificant, a trend for better kidney function was noted in this short-term study in the Advagraf group, so long-term follow-up is needed to verify this.
American Psychological Association (APA)
Bakr, Muhammad Adil& Najib, Ayman Mahir& Dunya, Ahmad Faruq& Abbas, Muhammad Hamid& Mashali, Muhammad al-Sayyid& Ghunaym, Muhammad Ahmad…[et al.]. 2018. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation : a prospective randomized trial. Saudi Journal of Kidney Diseases and Transplantation،Vol. 29, no. 6, pp.1267-1273.
https://search.emarefa.net/detail/BIM-896374
Modern Language Association (MLA)
Bakr, Muhammad Adil…[et al.]. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation : a prospective randomized trial. Saudi Journal of Kidney Diseases and Transplantation Vol. 29, no. 6 (Nov. / Dec. 2018), pp.1267-1273.
https://search.emarefa.net/detail/BIM-896374
American Medical Association (AMA)
Bakr, Muhammad Adil& Najib, Ayman Mahir& Dunya, Ahmad Faruq& Abbas, Muhammad Hamid& Mashali, Muhammad al-Sayyid& Ghunaym, Muhammad Ahmad…[et al.]. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation : a prospective randomized trial. Saudi Journal of Kidney Diseases and Transplantation. 2018. Vol. 29, no. 6, pp.1267-1273.
https://search.emarefa.net/detail/BIM-896374
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 1273
Record ID
BIM-896374